Kytopen
CAMBRIDGE, MA · Biotechnology · 34 employees
Kytopen, a spin-out of Prof. Cullen Buie’s lab at MIT, is a transformative biotechnology company that offers a customizable yet scalable multi-solution platform, which seamlessly links the discovery, development, and manufacturing phases of cell engineering. Flowfect®, a gentle, non-viral delivery method unlocks new therapeutic approaches, by engineering immune cells with minimal disruption, prese
Funding history
- Funding Round — $7.1M — Feb 2025
- Funding Round — $5.7M — Feb 2024
- Series series a — $30.0M — Sep 2021
Recent signals
- Feb 20, 2025: Raised $7.1M
- Apr 08, 2024: Kytopen Corp. Appoints Kevin Gutshall as Chief Commercial Officer
- Feb 15, 2024: Raised $5.7M
- Aug 07, 2023: Kytopen Names Michael Chiu, Ph.D., as Chief Executive Officer
- Sep 28, 2021: Raised $30.0M in Series series a
See plans & pricing → Track Kytopen’s funding, hiring, and signals — with verified contacts — on Fundz.